Table 2.
Characteristics of pulmonary patterns with [18F]FDG PET/CT in asymptomatic patients with COVID-19.
| Pattern of Lung Lesion | Number of Lung Lesions | Number of Affected Lobes | Distribution of Affected Lobes | Location of Affected Lobes | Lung Involvement | Location of Thoracic LN Involvement | Degree of [18F]FDG Uptake | References and Images |
|---|---|---|---|---|---|---|---|---|
|
Without lung lesion (n = 2)
(P21, P24) |
- | - | - | - | - | Hilar alone (n = 1) (P24) NR (n = 1) |
LN: SUVmax 2.6 (n = 1) (P24) NR (n = 1) |
[22]: Figure 4 (P21) [29]: Figure 1 (P24) |
|
GGO alone (n = 13)
(P2, P3, P6, P11, P14-20, P22, P27) |
Multiple (n = 13) | 1 lobe (n = 2) (P2, P19) 2 lobes (n = 2) (P3, P17) 3 lobes (n = 1) (P4) 5 lobes (n = 4) (P11, P15, P20, P22) NR (n = 4) |
PS (n = 1) (P6) SS (n = 4) (P2, P16-18) PS and SS (n = 1) (P3) NR (n = 7) |
RML (n = 1) (P19) RLL (n = 2) (P2, P6) RLL and LLL (n = 2) (P3, P17) Right lung lobes (n = 1) (P16) All lung lobes (n = 4) (P11, P15, P20, P22) NR (n = 3) |
Unilateral (n = 3) (P2, P16, P19) Bilateral (n = 10) (P3, P6, P11, P14, P15, P17 P18, P20, P22, P27) |
No involvement (n = 2) (P2, P11) Hilar alone (n = 1) (P18) Mediastinal alone (n = 1) (P15) Mediastinal and hilar (n = 1) (P6) Mediastinal, hilar, and carinal (n = 1) (P17) NR (n = 7) |
Lung lesion: No [18F]FDG uptake (n = 1) (P11) SUV max 2 to 12 (n = 8) (P2, P3, P6, P14-18) SUV lbm max 6.8 (n = 1) (P20) NR (n = 3) (P19, P20, P27) LN: SUVmax 2.5 to 9.6 (n = 3) (P6, P17, P18) NR (n = 10) |
[12]: Figures 2, 4 and 6 (P14, P15, P16) [15]: Figure 3 (P11) [19,20,25,28]: Figure 1 (P2, P3, P6, P27) [22]: Figures 2, 3 and 5 (P19, P20, P22) [23]: Figure 2 and Supplementary Figure 3 (P17, P18) |
|
GGO plus consolidation (n = 7)
(P5, P8, P9, P12, P13, P28, P29) |
Unique (n = 1) (P5) Multiple (n = 5) (P8, P12, P13, P28, P29) Mixed (n = 1) (P9) |
1 lobe (n = 1) (P5) 2 lobes (n = 3) (P9, P13) 3 lobes (n = 2) (P8, P12) 5 lobes (n = 1) (P28) |
PS (n = 3) (P8, P12, P28) SS (n = 1) (P29) NR (n = 3) (P5, P9, P13) |
RML (n = 1) (P5) RUL and LLL (n = 2) (P9, P29) RLL and LLL (n = 1) (P13) RUL, RLL, and LLL (n = 1) (P12) RLL and left lung lobes (n = 1) (P8) All lung lobes (n = 1) (P28) |
Unilateral (n = 1) (P5) Bilateral (n = 6) (P8, P9, P12, P13, P28, P29) |
Hilar alone (n = 1) (P12) Mediastinal and left subclavian (n = 1) (P8) Mediastinal, hilar, and carinal (n = 1) (P9) Mediastinal lymphadenopathy (n = 1) (P28) NR (n = 3) |
Lung lesion: SUVmax 3.3 to 8.1 (n = 4) (P5, P13, P28, P29) SUV bw max 3.6 to 10.7 (n = 3) (P8, P9, 12) LN: SUV bw max 3.9 to 5.9 (n = 3) (P8, P9, P12) NR (n = 4) |
[12,21,26]: Figure 1 (P5, P13, P28) [15]: Figures 1 and 4 (P8, P9, P12) [24]: Figures 1 and 2 (P29) |
|
GGO plus consolidation and
septal thickening (n = 1) (P10) |
Mixed | 2 lobes | PS | LUL and LLL | Unilateral | Mediastinal and hilar | Lung lesion: SUV bw max 3.3 (consolidation); 6.5 (GGOs) LN: SUV bw max 5.2 |
[15]: Figure 2 |
|
GGO plus consolidation and
curvilinear line (n = 1) (P30) |
Unique | 4 lobes | NR | Right lung lobes and LUL | Bilateral | NR | Lung lesion: SUVmax 5.4 |
[17]: Figure 1 |
|
GGO plus interlobular
thickening (n = 1) (P7) |
Unique | 1 lobe | PS | RLL | Unilateral | Ipsilateral hilar and subcarinal | Lung lesion: SUVmax 8 LN: SUVmax 5 |
[14]: Figure 1 |
| GGO plus intralobular thickening (n = 1) (P4) | Multiple | 2 lobes | NR | RLL and LUL | Bilateral | NR | NR | [27]: Figure 1 |
|
GGO plus tree-in-bud opacities
(n = 1) (P1) |
Multiple | NR | PS and SS | NR | Bilateral | NR | Lung lesion: SUVmax 2.4 |
[13]: Figure 1 |
| GGO plus crazy paving (n = 1) (P23) | Unique | 5 lobes | NR | All lung lobes | Bilateral | NR | Lung lesion: SUV lbm max 3.7 |
[22]: Figure 6 |
| GGO plus a nodule (n = 1) (P26) | Mixed | 3 lobes | PS | Right lung lobes | Unilateral | NR | Lung lesion: SUVmax 2.4 (GGOs) |
[16]: Figures 1 and 2 |
|
GGO plus curvilinear line,
thrombus, and lung infiltrates (n = 1) (P25) |
Multiple | NR | SS and CS | NR | Bilateral | Mediastinal and hilar | Lung lesion: SUVmax 3.2 LN: SUVmax 8.1 (mediastinal) |
[18]: Figure 1 |
-, without; PS, peripheral site; SS, subpleural site; CS, central site; NR, not reported.